cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.11583/dtu.23932014.v1
title: Pearl-net trials. Data collected from fishing trials testing if plastic pearls reduce the amount of fish catches.

description: The mitigation trials took place onboard a Danish commercial set net vessel during three distinct periods, in November 2022, February 2023, and May-June 2023 in the Western Baltic Sea. All trials were conducted with a standard 3-folds trammel net used in this area to target Atlantic cod and flatfish. We used 18 identical net panels of approximately 60 m in horizontal length, of which 5 net panels were equipped with acrylic pearls on one of the outer net layers, resulting in 13 control and 5 treatment panels. The pearls were small acrylic glass spheres (Ø 8 mm) with a groove (4 mm long and 0.8 mm wide) into which to fit the net thread.Each fishing day during the course of the trial, the fisher set one string of nets consisting of 6 control nets, then 5 pearl nets, and lastly 7 control nets. As a result, control nets and pearl nets were always deployed on the same fishing grounds, at the same time, and soaked in the water for the same duration. The trials were recorded using electronic monitoring (EM). The EM system installed onboard (Black Box Video, Anchorlab, Denmark) consisted of a control unit, associated with a position sensor (GPS), and two waterproof CCTV (closed-circuit television) cameras.The data set is made on haul basis. For each haul the date, number of control-nets, number of pearl-nets, Kg of all fish catches and numbers of cod (<i>Gadus Morhua</i>) is registered. The catches of fish (in kg) was noted by the fisher carrying out the trials whereas the numbers of cod caught was registered from video analysis of all net hauls.<br>
DOI: 10.6084/m9.figshare.23593103
title: <i>MPL</i> gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan

description: Since <i>MPL</i> mutation is a rare driver gene mutation found in a small number of essential thrombocythemia (ET) patients, the clinical characteristics of patients with <i>MPL</i> mutations and their association with thrombotic events have not yet been elucidated in Japan. We enrolled 579 Japanese ET patients based on the diagnostic criteria of the WHO classification 2017 and compared clinical characteristics of <i>MPL</i>-mutated patients (<i>n</i> = 22; 3.8%) to <i>JAK2</i>V617F-mutated (<i>n</i> = 299; 51.6%), <i>CALR</i>-mutated (<i>n</i> = 144; 24.9%), and triple-negative (TN) (<i>n</i> = 114; 19.7%) patients. Thrombosis during follow up was observed in 4 out of 22 (18.2%) in the <i>MPL</i>-mutated group, which was the highest among all driver gene mutation groups (<i>JAK2</i>V617F-mutated, 8.7%; <i>CALR</i>-mutated, 3.5%; TN,1.8%). The <i>MPL-</i> and <i>JAK2</i>V617F-mutated groups had worse thrombosis-free survival (TFS) than the <i>CALR</i>-mutated (<i>p</i> = 0.043) and TN groups (<i>p</i> = 0.006). Univariable analysis revealed that a history of thrombosis was a possible risk factor for thrombosis among <i>MPL</i>-mutated patients (hazard ratio: 9.572, <i>p</i> = 0.032). <i>MPL</i>-mutated ET patients should require more intensive management to prevent recurrence of thrombosis.
DOI: 10.6084/m9.figshare.23593103.v1
title: <i>MPL</i> gene mutation is a possible risk factor for thrombosis in patients with essential thrombocythemia in Japan

description: Since <i>MPL</i> mutation is a rare driver gene mutation found in a small number of essential thrombocythemia (ET) patients, the clinical characteristics of patients with <i>MPL</i> mutations and their association with thrombotic events have not yet been elucidated in Japan. We enrolled 579 Japanese ET patients based on the diagnostic criteria of the WHO classification 2017 and compared clinical characteristics of <i>MPL</i>-mutated patients (<i>n</i> = 22; 3.8%) to <i>JAK2</i>V617F-mutated (<i>n</i> = 299; 51.6%), <i>CALR</i>-mutated (<i>n</i> = 144; 24.9%), and triple-negative (TN) (<i>n</i> = 114; 19.7%) patients. Thrombosis during follow up was observed in 4 out of 22 (18.2%) in the <i>MPL</i>-mutated group, which was the highest among all driver gene mutation groups (<i>JAK2</i>V617F-mutated, 8.7%; <i>CALR</i>-mutated, 3.5%; TN,1.8%). The <i>MPL-</i> and <i>JAK2</i>V617F-mutated groups had worse thrombosis-free survival (TFS) than the <i>CALR</i>-mutated (<i>p</i> = 0.043) and TN groups (<i>p</i> = 0.006). Univariable analysis revealed that a history of thrombosis was a possible risk factor for thrombosis among <i>MPL</i>-mutated patients (hazard ratio: 9.572, <i>p</i> = 0.032). <i>MPL</i>-mutated ET patients should require more intensive management to prevent recurrence of thrombosis.
DOI: 10.6084/m9.figshare.22241468
title: Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies

description: Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis. Methods: Databases and the Clinical Registration Platforms have been systematically searched for related studies by March 2022. For safety analysis, the incidence and exhibition of any grade and grade 3 or higher adverse effects (AEs) were evaluated. Besides, severe AEs (SAEs), treatment-related deaths, and AEs leading to treatment discontinuation were summarized. The overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, progression-free survival (PFS), overall survival (OS), and duration of response (DOR) were calculated for efficacy analysis. All processes were implemented mainly through the package Meta and MetaSurv of software R 4.1.2. Results: Overall 20 studies and 1440 patients were enrolled. The pooled incidence of any grade and grade 3 or higher AEs were 92% and 26%, respectively. The pooled ORR, CR rate and PR rate were 79%, 44% and 34%, respectively. The most common AEs were neuropathy (29%), nausea (27%), pyrexia (26%), and leukopenia (25%), and the most common grade 3 or higher AEs included leukopenia (10%), infusion reaction (8%), weight gain (3%), and neutropenia (2.7%). In survival analysis, pembrolizumab monotherapy appeared to perform better compared to nivolumab monotherapy. Conclusions: PD-1/PD-L1 inhibitors show promising efficacy and tolerable AEs in the treatment of R/R HL.
DOI: 10.6084/m9.figshare.22241468.v1
title: Safety and efficacy of PD-1 and PD-L1 inhibitors in relapsed and refractory Hodgkin's lymphoma: a systematic review and meta-analysis of 20 prospective studies

description: Background: Inhibitors of programmed cell death protein 1 (PD-1) and programmed cell death ligand 1 (PD-L1) have been used in the treatment of relapsed and refractory Hodgkin's lymphoma (R/R HL) recently. To further understand the safety and efficacy of PD-1/PD-L1 inhibitors in R/R HL, we conducted this meta-analysis. Methods: Databases and the Clinical Registration Platforms have been systematically searched for related studies by March 2022. For safety analysis, the incidence and exhibition of any grade and grade 3 or higher adverse effects (AEs) were evaluated. Besides, severe AEs (SAEs), treatment-related deaths, and AEs leading to treatment discontinuation were summarized. The overall response rate (ORR), complete response (CR) rate, partial response (PR) rate, progression-free survival (PFS), overall survival (OS), and duration of response (DOR) were calculated for efficacy analysis. All processes were implemented mainly through the package Meta and MetaSurv of software R 4.1.2. Results: Overall 20 studies and 1440 patients were enrolled. The pooled incidence of any grade and grade 3 or higher AEs were 92% and 26%, respectively. The pooled ORR, CR rate and PR rate were 79%, 44% and 34%, respectively. The most common AEs were neuropathy (29%), nausea (27%), pyrexia (26%), and leukopenia (25%), and the most common grade 3 or higher AEs included leukopenia (10%), infusion reaction (8%), weight gain (3%), and neutropenia (2.7%). In survival analysis, pembrolizumab monotherapy appeared to perform better compared to nivolumab monotherapy. Conclusions: PD-1/PD-L1 inhibitors show promising efficacy and tolerable AEs in the treatment of R/R HL.
DOI: 10.6084/m9.figshare.24640113
title: Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis

description: The role of subcutaneous (SC) rituximab in the efficacy and safety to non-Hodgkin lymphoma (NHL) is not clear enough. The purpose of this study was to conduct a systematic review and meta-analysis, to assess the efficacy and safety of subcutaneous rituximab to NHL. A full-scale search was carried out based on the set search terms in PubMed, Web of Science, Embase and Cochrane CENTRAL until 12 October 2022 to identify relevant studies of subcutaneous rituximab for NHL. The efficacy and safety outcomes included complete response (CR) plus unconfirmed complete response (CRu), adverse events (AEs), grade ≥3 AEs, serious adverse events (SAEs), administration-related reactions (ARRs), adverse reaction rates. From a total of 758 studies, 9 trials were eligible. The CR/CRu of patients with NHL receiving SC rituximab was 57%, 55% for Diffuse large B-cell lymphoma (DLBCL) and 54% for Follicular lymphoma (FL). The meta-analysis performed on safety demonstrated that AEs of NHL patients with SC rituximab was 85%, grade ≥3 AEs was 38%, SAE was 27% and ARR was 33%. The result also showed that SC rituximab had a high risk of neutropenia and nausea. For NHL patients, there is no significant difference in the efficacy between subcutaneous rituximab and conventional therapy, while subcutaneous injection can shorten exposure time in the hospital and reduce the risk of infection.
DOI: 10.6084/m9.figshare.24640113.v1
title: Clinical efficacy and safety of subcutaneous rituximab in non-Hodgkin lymphoma: a systematic literature review and meta-analysis

description: The role of subcutaneous (SC) rituximab in the efficacy and safety to non-Hodgkin lymphoma (NHL) is not clear enough. The purpose of this study was to conduct a systematic review and meta-analysis, to assess the efficacy and safety of subcutaneous rituximab to NHL. A full-scale search was carried out based on the set search terms in PubMed, Web of Science, Embase and Cochrane CENTRAL until 12 October 2022 to identify relevant studies of subcutaneous rituximab for NHL. The efficacy and safety outcomes included complete response (CR) plus unconfirmed complete response (CRu), adverse events (AEs), grade ≥3 AEs, serious adverse events (SAEs), administration-related reactions (ARRs), adverse reaction rates. From a total of 758 studies, 9 trials were eligible. The CR/CRu of patients with NHL receiving SC rituximab was 57%, 55% for Diffuse large B-cell lymphoma (DLBCL) and 54% for Follicular lymphoma (FL). The meta-analysis performed on safety demonstrated that AEs of NHL patients with SC rituximab was 85%, grade ≥3 AEs was 38%, SAE was 27% and ARR was 33%. The result also showed that SC rituximab had a high risk of neutropenia and nausea. For NHL patients, there is no significant difference in the efficacy between subcutaneous rituximab and conventional therapy, while subcutaneous injection can shorten exposure time in the hospital and reduce the risk of infection.
DOI: 10.6084/m9.figshare.22331658
title: Whole exome sequencing and rare variant association study to identify genetic modifiers, <i>KLF1</i> mutations, and a novel double mutation in Thai patients with hemoglobin E/beta-thalassemia

description: Clinical manifestations of patients with Hemoglobin E/beta-thalassemia vary from mild to severe phenotypes despite exhibiting the same genotype. Studies have partially identified genetic modifiers. We aimed to study the association between rare variants in protein-coding regions and clinical severity in Thai patients. From April to November 2018, a case–control study was conducted based on clinical information and DNA samples collected from Thai patients with hemoglobin E/beta-thalassemia over the age of four years. Cases were patients with severe symptoms, while patients with mild symptoms acted as controls. Whole exome sequencing and rare variant association study were used to analyze the data. All 338 unrelated patients were classified into 165 severe and 173 mild cases. Genotypes comprised 81.4% of hemoglobin E/beta-thalassemia, 2.7% of homozygous or compound heterozygous beta-thalassemia, and 0.3% of (δβ)<sup>0</sup> thalassemia Hb E while 15.7% of samples were not classified as beta-thalassemia. A novel cis heterozygotes of IVS I-7 (A &gt; T) and codon 26 (G &gt; A) was identified. Six genes (<i>COL4A3</i>, <i>DLK1</i>, <i>FAM186A</i>, <i>PZP</i>, <i>THPO</i>, and <i>TRIM51</i>) showed the strongest associations with severity (observed <i>p</i>-values of &lt;0.05; significance lost after correction for multiplicity). Among known modifiers, <i>KLF1</i> variants were found in four mild patients and one severe patient. No rare variants were identified as contributors to the clinical heterogeneity of hemoglobin E/beta-thalassemia. <i>KLF1</i> mutations are potential genetic modifiers. Studies to identify genetic factors are still important and helpful for predicting severity and developing targeted therapy.
DOI: 10.6084/m9.figshare.22331658.v1
title: Whole exome sequencing and rare variant association study to identify genetic modifiers, <i>KLF1</i> mutations, and a novel double mutation in Thai patients with hemoglobin E/beta-thalassemia

description: Clinical manifestations of patients with Hemoglobin E/beta-thalassemia vary from mild to severe phenotypes despite exhibiting the same genotype. Studies have partially identified genetic modifiers. We aimed to study the association between rare variants in protein-coding regions and clinical severity in Thai patients. From April to November 2018, a case–control study was conducted based on clinical information and DNA samples collected from Thai patients with hemoglobin E/beta-thalassemia over the age of four years. Cases were patients with severe symptoms, while patients with mild symptoms acted as controls. Whole exome sequencing and rare variant association study were used to analyze the data. All 338 unrelated patients were classified into 165 severe and 173 mild cases. Genotypes comprised 81.4% of hemoglobin E/beta-thalassemia, 2.7% of homozygous or compound heterozygous beta-thalassemia, and 0.3% of (δβ)<sup>0</sup> thalassemia Hb E while 15.7% of samples were not classified as beta-thalassemia. A novel cis heterozygotes of IVS I-7 (A &gt; T) and codon 26 (G &gt; A) was identified. Six genes (<i>COL4A3</i>, <i>DLK1</i>, <i>FAM186A</i>, <i>PZP</i>, <i>THPO</i>, and <i>TRIM51</i>) showed the strongest associations with severity (observed <i>p</i>-values of &lt;0.05; significance lost after correction for multiplicity). Among known modifiers, <i>KLF1</i> variants were found in four mild patients and one severe patient. No rare variants were identified as contributors to the clinical heterogeneity of hemoglobin E/beta-thalassemia. <i>KLF1</i> mutations are potential genetic modifiers. Studies to identify genetic factors are still important and helpful for predicting severity and developing targeted therapy.
DOI: 10.23729/939a4cc8-de7b-47d6-8e95-14777c2e3ce6
title: HITEC EB14

description: EB13 samples of HITEC. Collective preview dataset at https://doi.org/10.23729/170132f5-ecba-4dc8-b248-001dc5795db5 . Preview dataset found at https://doi.org/10.23729/7325c282-83d7-433a-be65-a905faa81d03 . To obtain data, please contact fairdata-pas@gtk.fi .
DOI: 10.5281/zenodo.8337701
title: Repetitive Transcranial Magnetic Stimulation of the human motor cortex modulates processing of heat pain sensation as assessed by the offset analgesia paradigm

description: Heat pain threshold (HPT) values and Visual Analogue Scale (VAS) values recorded during a constant trial and an offset analgesia trial recorded at baseline and after active or sham  repetitive Transcranial Magnetic Stimulation (rTMS).  T1, T2 and T3 indicate different time intervals of OA trial, i.e., T1 = first 5 s interval of the individualized HPT, T2 = 5 s interval at a temperature 1 ˚C higher than T1, T3 = 20 s interval at the same temperature as T1. Constant trial included 30 s of a stimulus at HPT.
DOI: 10.5281/zenodo.8337700
title: Repetitive Transcranial Magnetic Stimulation of the human motor cortex modulates processing of heat pain sensation as assessed by the offset analgesia paradigm

description: Heat pain threshold (HPT) values and Visual Analogue Scale (VAS) values recorded during a constant trial and an offset analgesia trial recorded at baseline and after active or sham  repetitive Transcranial Magnetic Stimulation (rTMS).  T1, T2 and T3 indicate different time intervals of OA trial, i.e., T1 = first 5 s interval of the individualized HPT, T2 = 5 s interval at a temperature 1 ˚C higher than T1, T3 = 20 s interval at the same temperature as T1. Constant trial included 30 s of a stimulus at HPT.
DOI: 10.5281/zenodo.10212503
title: Converting raw birch suberin into vitrimer

description: The xlsx file contains numeric data for figures that were included in the paper entitled "Converting raw birch suberin into vitrimer"
These include:

Flow curve of suberin resin
DSC of suberin resin
Rheometric curves of suberin resin in the presence of various catalysts 
The influence of a catalyst on suberin thermoset stress relaxation
The influence of DBTDL concentration on suberin thermoset stress relaxation
The influence of temperature on suberin thermoset stress relaxation
Creep-recovery of suberin vitrimer
Stress relaxation of repolymerized suberin vitrimer 
TGA of suberin vitrimer
DSC of raw and recycled suberin vitrimer
Mechanical performance of raw and recycled suberin vitrimer
Amplitude sweep test of suberin vitrimer
Frequency sweep test of suberin vitrimer
DMTA data of suberin vitrimer
1H NMR Data of suberin resin
Hydrolytic degradation data of suberin vitrimer
Soil degradation data of suberin vitrimer
DOI: 10.5281/zenodo.10212504
title: Converting raw birch suberin into vitrimer

description: The xlsx file contains numeric data for figures that were included in the paper entitled "Converting raw birch suberin into vitrimer"
These include:

Flow curve of suberin resin
DSC of suberin resin
Rheometric curves of suberin resin in the presence of various catalysts 
The influence of a catalyst on suberin thermoset stress relaxation
The influence of DBTDL concentration on suberin thermoset stress relaxation
The influence of temperature on suberin thermoset stress relaxation
Creep-recovery of suberin vitrimer
Stress relaxation of repolymerized suberin vitrimer 
TGA of suberin vitrimer
DSC of raw and recycled suberin vitrimer
Mechanical performance of raw and recycled suberin vitrimer
Amplitude sweep test of suberin vitrimer
Frequency sweep test of suberin vitrimer
DMTA data of suberin vitrimer
1H NMR Data of suberin resin
Hydrolytic degradation data of suberin vitrimer
Soil degradation data of suberin vitrimer
DOI: 10.5281/zenodo.10345842
title: Influence of lateral shear on the formation of Enceladus' South Polar Terrain (data)

description: This repository contains the numerical results of case {0.8, 25, 40} as well as the parameter file and the plugin files for the modeling. The finite element code elASPECT that runs the model is available at https://github.com/YiminJin/elaspect. One can reproduce all the results presented in the paper by modifying the parameter entries "Ice thickness", "Maximum depression", "Outer radius" and "Inner radius".
DOI: 10.5281/zenodo.10345841
title: Influence of lateral shear on the formation of Enceladus' South Polar Terrain (data)

description: This repository contains the numerical results of case {0.8, 25, 40} as well as the parameter file and the plugin files for the modeling. The finite element code elASPECT that runs the model is available at https://github.com/YiminJin/elaspect. One can reproduce all the results presented in the paper by modifying the parameter entries "Ice thickness", "Maximum depression", "Outer radius" and "Inner radius".
DOI: 10.25392/leicester.data.24786912
title: Data related to "A dynamic attractor network model of memory formation, reinforcement and forgetting"

description:   
The dataset contains the data underlying the results presented in:
Boscaglia, M., Gastaldi, C., Gerstner, W., & Quiroga, R.Q., “A dynamic attractor network model of memory formation, reinforcement and forgetting”.
The data show the results of the simulations performed with a rate attractor network model characterized by: an online Hebbian learning rule, background firing activity, neural adaptation and heterosynaptic plasticity.
All the data can be directly linked to the figures and results shown in the main text and in the supplementary information of the related manuscript.
DOI: 10.25392/leicester.data.24786912.v1
title: Data related to "A dynamic attractor network model of memory formation, reinforcement and forgetting"

description:   
The dataset contains the data underlying the results presented in:
Boscaglia, M., Gastaldi, C., Gerstner, W., & Quiroga, R.Q., “A dynamic attractor network model of memory formation, reinforcement and forgetting”.
The data show the results of the simulations performed with a rate attractor network model characterized by: an online Hebbian learning rule, background firing activity, neural adaptation and heterosynaptic plasticity.
All the data can be directly linked to the figures and results shown in the main text and in the supplementary information of the related manuscript.
DOI: 10.6084/m9.figshare.24787278
title: Supplementary Material for: A low-cost, high-fidelity simulator for transabdominal chorionic villus sampling

description: Introduction: Chorionic villus sampling (CVS) remains essential for first trimester genetic diagnosis, yet clinical volume may be insufficient to train new clinicians in the technique. Available simulation models are expensive, require animal parts or specialized resins, and cannot be stored for repeated use.

Methods: We present a model for trans-abdominal CVS (TA-CVS) which is constructed from readily-available materials costing less than $10 and can be refrigerated and re-used to train maternal fetal medicine (MFM) fellows in CVS.

Results: All three attending physicians performing TA-CVS at our institution described the model as an accurate visual and tactile simulation, prompting its integration into our fellowship curriculum. To date, two senior fellows have achieved competency on the simulator and begun to perform clinical CVS under supervision, one of whom is an author on this paper. Both fellows and attendings indicated that the simulator provided a valuable tool for repeated practice prior to clinical CVS. Simulators are now maintained on the unit and have been re-used for three months and dozens of simulated procedures each without any apparent qualitative degradation in performance.

Discussion/Conclusion: We describe a low-cost easily constructed, durable, high-fidelity simulator for TA-CVS.